Overview

A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Status:
Not yet recruiting
Trial end date:
2022-06-08
Target enrollment:
Participant gender:
Summary
The study will be conducted to evaluate the safety and tolerability of SHR-1819 injection and describe the PK/PD/ADA and explore the clinical efficacy.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai Hengrui Pharmaceutical Co., Ltd.